The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic and predictive significance of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
Karen A. Gelmon
No relevant relationships to disclose
Judy-Anne W. Chapman
No relevant relationships to disclose
Shuzhen Liu
Research Funding - NanoString Technologies
Margot J. Burnell
Other Remuneration - Roche
Mark Norman Levine
No relevant relationships to disclose
Kathleen I. Pritchard
No relevant relationships to disclose
Timothy Joseph Whelan
No relevant relationships to disclose
Hope S. Rugo
No relevant relationships to disclose
Kathy S. Albain
Consultant or Advisory Role - NanoString Technologies
Edith A. Perez
No relevant relationships to disclose
Shakeel Virk
No relevant relationships to disclose
Patti O'Brien
No relevant relationships to disclose
Lois E. Shepherd
No relevant relationships to disclose
Torsten O. Nielsen
Consultant or Advisory Role - Bioclassifier; NanoString Technologies
Stock Ownership - Bioclassifier
Research Funding - NanoString Technologies
Other Remuneration - NanoString Technologies